Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

Schimanski, CC; Kasper, S; Hegewisch-Becker, S; Schroder, J; Overkamp, F; Kullmann, F; Bechstein, WO; Vohringer, M; Ollinger, R; Lordick, F; Heinemann, V; Geissler, M; Schulz-Abelius, A; Bernhard, H; Schon, MR; Greil, R; Galle, P; Lang, H; Schmidtmann, I; Moehler, M ONCOIMMUNOLOGY. 2020; 9(1): 1806680

Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial

Papakonstantinou, A; Matikas, A; Bengtsson, NO; Malmstrom, P; Hedayati, E; Steger, G; Untch, M; Hubbert, L; Johansson, H; Hellstrom, M; Gnant, M; Loibl, S; Greil, R; Moebus, V; Foukakis, T; Bergh, J CANCER-AM CANCER SOC. 2020;

Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Huemer, F; Weiss, L; Regitnig, P; Winder, T; Hartmann, B; Thaler, J; Piringer, G; Schmitt, CA; Eisterer, W; Gänzer, H; Wüstner, A; Andel, J; Jagdt, B; Ulmer, H; Greil, R; Wöll, E; J Clin Med. 2020; 9(4):

The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine:

Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Woll, E; Gerger, A THER ADV MED ONCOL. 2020; 12: 1758835919900872

Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Schwitter, M; Zaman, K; Jerusalem, G; Cazzaniga, M; Greil, R; Ursula, US; Mueller, A; Nussbaum, CU; Auteri, A; Rothgiesser, K; Dietrich, D; Ruhstaller, T CANCER RES. 2021; 81(4):

First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry

Rinnerthaler, G; Gampenrieder, SP; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2021; 81(4):

Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry

Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2021; 81(4):

Overall Survival with Tafasitamab plus Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study

Nowakowski, GS; Yoon, DH; Mondello, P; Joffe, E; Peters, A; Fleury, I; Greil, R; Ku, M; Marks, R; Kim, K; Zinzani, PL; Trotman, J; Huang, D; Waltl, EE; Winderlich, M; Ambarkhane, S; Hess, G; Salles, G CL LYMPH MYELOM LEUK. 2021; 21: S392-S393.

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Tilly, H; Morschhauser, F; Sehn, LH; Friedberg, JW; Trneny, M; Sharman, JP; Herbaux, C; Burke, JM; Matasar, M; Rai, S; Izutsu, K; Mehta-Shah, N; Oberic, L; Chauchet, A; Jurczak, W; Song, YQ; Greil, R; Mykhalska, L; Burgues, JMB; Cheung, MC; Pinto, A; Shin, HJ; Hapgood, G; Munhoz, E; Costa, PA; Gau, JP; Hirata, J; Jiang, YW; Yan, M; Lee, C; Flowers, CR; Salles, G BLOOD. 2021; 138:

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Nowakowski, GS; Yoon, DH; Mondello, P; Joffe, E; Fleury, I; Peters, A; Greil, R; Ku, M; Marks, R; Kim, K; Zinzani, PLL; Trotman, J; Sabatelli, L; Huang, D; Waltl, EE; Winderlich, M; Ambarkhane, S; Kurukulasuriya, NC; Cordoba, R; Hess, G; Salles, G BLOOD. 2021; 138: